ReNeuron Group plc Notification of Preliminary Results (4649H)
June 08 2017 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 4649H
ReNeuron Group plc
08 June 2017
AIM: RENE 8 June
2017
ReNeuron Group plc
Notification of Preliminary Results
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics, will
announce its preliminary results for the year ended 31 March 2017
on Thursday 29 June 2017.
A meeting for analysts will be held at 9.00am on the morning of
the results announcement at the offices of Buchanan, 107 Cheapside,
London EC2V 6DN.
To access a webcast of the analyst presentation, please log on
to the following web address approximately 10 minutes before 9.00am
on the day of the results:
http://vm.buchanan.uk.com/2017/reneuron290617/registration.htm
A recording of the presentation will be made available on
ReNeuron's website, www.reneuron.com.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for motor disability as a result of stroke, for
critical limb ischaemia and for the blindness-causing disease,
retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for gene therapy treatments.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORSSAFIWFWSELM
(END) Dow Jones Newswires
June 08, 2017 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024